WP16302 a bioequivalence study comparing ganciclovir from the valganciclovir syrup formulation and the commercial valganciclovir 450mg tablet (Valcyte) at a dose of 900mg in kidney transplant recipients, sponsor protocol dated 8/11/2005 and investigator brochure version August 2005.
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2009
At a glance
- Drugs Ganciclovir; Valganciclovir
- Indications Cytomegalic inclusion disorders
- Focus Pharmacokinetics
- 29 Mar 2007 New trial record.